Advances in precision oncology have transformed the treatment landscape for many patients with non-small cell lung cancer (NSCLC). Rather than treating all lung cancers in the same way, modern therapies increasingly target specific molecular alterations that drive tumour growth.
One such alteration involves the MET gene, particularly MET exon 14 skipping mutations, which occur in a small but clinically important subset of lung cancers.
For patients with these alterations, MET-targeted therapies offer a personalised treatment approach designed to inhibit the biological pathways that allow cancer cells to grow and spread.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhat Is MET Exon 14 Lung Cancer?
MET exon 14 lung cancer refers to a subtype of non-small cell lung cancer caused by alterations in the MET gene that prevent normal degradation of the MET receptor. This leads to continuous activation of signalling pathways that promote tumour growth and survival.
Patients with MET exon 14 skipping mutations may benefit from targeted therapies known as MET inhibitors, which specifically block this abnormal pathway.
Understanding MET Alterations in Lung Cancer
The MET gene plays a key role in regulating cell growth, tissue repair and cell survival. Under normal circumstances, MET signalling is tightly controlled.
However, genetic alterations can disrupt this balance.
The most clinically relevant alteration is MET exon 14 skipping, which allows the MET receptor to remain active for longer than normal.
This abnormal signalling promotes tumour growth and spread.
MET exon 14 skipping mutations occur in approximately 3–4% of non-small cell lung cancer cases, making them an uncommon but important therapeutic target.
How MET-Driven Lung Cancer Is Diagnosed
Because MET alterations cannot be identified through imaging alone, molecular testing is essential.
Testing is usually performed on tumour tissue obtained during biopsy. In some situations, liquid biopsy using circulating tumour DNA may also be considered.
Comprehensive molecular testing allows doctors to identify:
- MET exon 14 skipping mutations
- other targetable alterations such as EGFR, ALK or ROS1
- biomarkers that influence treatment decisions
Identifying these molecular drivers allows oncologists to tailor treatment strategies to the specific biology of the tumour.
Key Steps in Identifying MET-Driven Lung Cancer
Diagnosing MET-altered lung cancer typically involves the following steps:
- Imaging tests such as CT or PET-CT to identify lung tumours
- Tissue biopsy to confirm the presence of cancer
- Pathological analysis to determine tumour subtype
- Molecular testing to detect MET exon 14 skipping mutations
- Multidisciplinary team (MDT) discussion to determine treatment strategy
This structured process helps ensure that patients receive the most appropriate personalised treatment.
MET-Targeted Therapies
Targeted therapies known as MET inhibitors are designed to block the abnormal MET signalling pathway that drives tumour growth.
These drugs interfere with cellular signals that allow cancer cells to proliferate and survive.
MET inhibitors may be used:
- as first-line treatment in selected patients
- after other systemic therapies
- within clinical trials evaluating new targeted approaches
Unlike traditional chemotherapy, targeted therapies act on specific molecular mechanisms within cancer cells.
For appropriately selected patients, this approach can lead to improved disease control while maintaining quality of life.
Managing Side Effects of MET Inhibitors
Although targeted therapies are often better tolerated than traditional chemotherapy, they can still produce side effects.
One of the most frequently observed toxicities with MET inhibitors is peripheral oedema, which causes swelling in the legs or other parts of the body.
Other potential side effects may include:
- fatigue
- gastrointestinal symptoms
- appetite changes
- abnormalities in liver function tests
Early recognition and appropriate management of treatment-related toxicities are important in order to maintain therapy safely.
Oncology teams closely monitor patients and adjust treatment where necessary.
The Role of Precision Oncology
The emergence of targeted therapies such as MET inhibitors highlights the growing importance of precision oncology in lung cancer.
Rather than relying solely on traditional chemotherapy, oncologists increasingly tailor treatment strategies based on the molecular profile of each patient’s tumour.
This personalised approach allows treatments to be matched to the biological drivers of the disease, improving the potential for effective disease control.
Expert Perspective from International Oncology Meetings
During the recent European Society for Medical Oncology (ESMO) Congress in Berlin and the British Thoracic Oncology Group (BTOG) Annual Meeting, Dr Dionysios Papadatos-Pastos, Consultant Thoracic Medical Oncologist in London, participated in specialist workgroups focused on the evolving role of MET-targeted therapies in non-small cell lung cancer.
These meetings brought together leading lung cancer experts, researchers and clinicians from the UK and internationally to exchange insights on the implementation of MET inhibitor therapies in routine clinical practice, particularly for patients with MET exon 14 skipping alterations.
Discussions focused not only on treatment strategies but also on the recognition and management of side effects associated with MET-targeted therapies, including drug-induced peripheral oedema and other treatment-related toxicities.
Sharing real-world clinical experience and emerging evidence helps ensure that patients benefit from safe, effective and personalised treatment approaches.
Participation in international oncology meetings such as ESMO and BTOG allows Dr Papadatos-Pastos to remain at the forefront of advances in precision medicine for lung cancer, helping ensure that patients in London have access to the latest targeted therapies, clinical trials and evidence-based treatment strategies.
Conclusion
MET-driven lung cancers represent a distinct molecular subtype of non-small cell lung cancer that can benefit from targeted treatment approaches.
Through comprehensive molecular testing and the use of MET inhibitors where appropriate, oncologists are increasingly able to tailor therapies to the genetic characteristics of each patient’s tumour.
As precision oncology continues to evolve, targeted therapies for MET alterations are expected to play an increasingly important role in the management of selected lung cancer patients.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Answers to common questions about MET exon 14 lung cancer, including how MET mutations are diagnosed, how MET inhibitors work and when targeted therapies are used in non-small cell lung cancer (NSCLC).
MET exon 14 skipping is a genetic alteration that activates the MET signalling pathway, allowing cancer cells to grow and survive.
MET exon 14 skipping mutations occur in approximately 3–4% of patients with non-small cell lung cancer.
MET inhibitors are targeted therapies designed to block abnormal MET signalling in cancers with MET exon 14 mutations.
Comprehensive molecular testing is often recommended for patients with advanced non-small cell lung cancer to identify targetable alterations such as MET mutations.
Peripheral oedema, fatigue and gastrointestinal symptoms are among the side effects that may occur, although many are manageable with medical supervision.
